SCHEMBL19913402

SCHEMBL19913402

CC(C)S(=O)(=O)c1ccn(C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.36
KMT2A Q03164 1/20 0.35
KEAP1 Q14145 1/20 0.33
TRPA1 O75762 1/20 0.33
GCK P35557 1/20 0.33
JMJD6 Q6NYC1 3/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CCR2 P41597 1/20 0.32
AURKA O14965 1/20 0.31
AURKB Q96GD4 1/20 0.31
HTR6 P50406 1/20 0.31
CYBB P04839 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
FGFR4 P22455 1/20 0.30
RIPK1 Q13546 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552 0.75 KMT2A (0.38) NLRP3KMT2AKEAP1JMJD6KDM4E
SCHEMBL2173254 0.75 KEAP1 (0.39) NLRP3KMT2AKEAP1JMJD6KDM4E
Hydrochloric Acid SCHEMBL27668438 0.73 NLRP3 (0.40) NLRP3KMT2AKEAP1JMJD6KDM4E
SCHEMBL23082978 0.72 CYP19A1 (0.36) NLRP3KMT2AKDM4ELMNAHTT
SCHEMBL15473846 0.72 NLRP3 (0.48) NLRP3KMT2AKEAP1KDM4EALDH1A1
SCHEMBL22871837 0.72 L3MBTL1 (0.38) NLRP3KMT2AKEAP1JMJD6KDM4E
SCHEMBL31442338 0.72 KEAP1 (0.37) NLRP3KMT2AKEAP1JMJD6KDM4E
SCHEMBL22942881 0.72 KMT2A (0.41) NLRP3KMT2AKEAP1JMJD6KDM4E
SCHEMBL16894114 0.68 TRPA1 (0.49) NLRP3TRPA1JMJD6KDM4EALDH1A1
SCHEMBL15471150 0.68 NLRP3 (0.42) NLRP3KMT2AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3150592-B1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) 2023-08-30 EP disclosed
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SPARCBIO LLC 2023-01-26 US disclosed
US-11332463-B2 Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors MERCK SHARP & DOHME CORP. (US) 2022-05-17 US disclosed
US-20210070745-A1 SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2021-03-11 US disclosed
US-20180057505-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY VERTEX PHARMACEUTICALS INCORPORATED 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332463-B2 Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors CHRNA7, CHRNA5, CHRNA6 NLRP3 1363/4885KMT2A 3815/4885KEAP1 1336/4885
US-20180057505-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY F2RL1, PARP12, TFPI2 NLRP3 352/4885KMT2A 3714/4885KEAP1 280/4885
US-20210070745-A1 SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS CHRNA7, CHRNA5, CHRNA6 NLRP3 1363/4885KMT2A 3815/4885KEAP1 1336/4885
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS NLRP3 3836/4885KMT2A 1917/4885KEAP1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.